Company intelligence / Profile preview
Odimma Therapeutics
Strasbourg, Grand Est, Franceodimma-therapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Odimma Therapeutics has completed proof-of-concept studies demonstrating strong anti-tumor effects of its lead personalized immunotherapy candidate ODI‑2001 in several aggressive preclinical cancer models. The company has secured manufacturing partnerships and funding to support regulatory activities and the initiation of a first-in-human Phase I clinical trial targeting advanced solid tumors.
- Therapeutic areas
- Oncology
- Modalities
- Personalized immunotherapy (synthetic DNA-based)Viral vector-based therapiesAI-enabled neoepitope prediction
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
myNEO (Belgium): AI-driven neoepitope predictionTouchlight Genetics (UK): Synthetic DNA productionABL Europe (France): Viral component manufacturing
Beyond the preview
Go deeper on Odimma Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Odimma Therapeutics.